Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (prevention of nausea and vomiting) View HTML
Toggle Summary (Hebrew) RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (prevention of nausea and vomiting) View HTML
Toggle Summary (Hebrew) RedHill Biopharma obtains a CTA approval from Health Canada to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) View HTML
Toggle Summary RedHill Biopharma obtains a CTA approval from Health Canada to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) View HTML
Toggle Summary Mr. Gilead Raday's interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients)
Mr. Gilead Raday's interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients) ...
View HTML
Toggle Summary IntelGenx, RedHill's Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial View HTML
Toggle Summary Dr. Jeff Lehighton presents RedHill Biopharma on Bloomberg TV
Dr. Jeff Lehighton presents RedHill Biopharma on Bloomberg TV ...
View HTML
Toggle Summary RedHill Biopharma engages with CRO for potential pivotal trial with RHB-102 (prevention of nausea & vomiting in cancer patients) View HTML
Toggle Summary (Hebrew) RedHill Biopharma engages with CRO for potential pivotal trial with RHB-102 (prevention of nausea & vomiting in cancer patients) View HTML
Toggle Summary RedHill Biopharma appoints Prof. Colm O'Morain, MD as Lead Investigator for the European Phase III trial with RHB-104 (Crohn's) View HTML